Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha

Uni-Bio Science Group Limited recently marked a pivotal moment in the medical aesthetics and healthcare landscape with a grand product launch in Changsha on June 27, 2025. This significant event saw the unveiling of their high-end medical aesthetics series, GeneQueens™ (Human-Sequence Triple Protein Repair & Balance Ampoule), and the innovative medical device brand, 金因敷®. Attended by a distinguished assembly of experts, key opinion leaders, and industry partners, the launch not only underscored the Group’s robust advancements in research and development but also solidified its comprehensive strategic presence across the burgeoning “drug, medical device, and Aesthetics” sectors, signaling a new era for personalized skin health solutions.

Central to the unveiling was the GeneQueens™ series, presented as a breakthrough in high-end medical aesthetics. This advanced line is meticulously formulated for superior skin repair and anti-aging, primarily by activating cellular regeneration to restore youthful and healthy skin conditions. Its efficacy is rooted in a unique combination of three core ingredients in precise quantities: Skbrella FN, crucial for accelerating skin wound healing and promoting new cell adhesion; III Collagen, which significantly enhances skin elasticity and firmness by reinforcing its structure; and XVII Collagen, vital for strengthening the connection between the epidermis and dermis, thereby consolidating the skin’s foundational youth. Furthermore, GeneQueens™ boasts a sterile, preservative-free formula, leveraging high-purity raw materials and patented technology to deliver an immediate, precise, and highly efficient skincare experience, garnering high praise from attending experts for its innovative approach.

Parallel to the GeneQueens™ launch, Uni-Bio Science Group also introduced a diverse range of new products under its medical device brand, 金因敷®. These products are specifically designed for professional repair within the medical aesthetics field, emphasizing safety and effectiveness through rigorous clinical trials and stringent quality inspections. 金因敷® features a high-purity, non-allergenic formula that not only moisturizes but also significantly accelerates wound repair. A standout innovation is its exclusive cooling technology, engineered to alleviate post-operative swelling and pain, positioning 金因敷® as an indispensable professional solution for sensitive skin and comprehensive post-medical procedure care, offering relief and promoting faster recovery for patients.

Further reinforcing its scientific credibility, 肌顏態® — the product line under which GeneQueens™ falls — showcased compelling research data at the 30th Academic Conference of the Chinese Medical Association (CSD2025). The efficacy study, “The Efficacy Study of Fibronectin in the Repair of Skin Barrier Damage for the post-medical procedure,” conducted jointly with the Cosmetics Testing Center of the Dermatology Hospital of Southern Medical University, was prominently displayed in the poster area. This presentation at CSD2025, a premier annual event in Chinese dermatology drawing authoritative experts and scholars, not only validated Uni-Bio Science Group’s profound research capabilities but also provided a critical platform for industry professionals to gain deeper insights into the advanced technology and superior products offered by 肌顏態®.

During the launch event, several prominent clinical experts provided compelling testimonials, collectively affirming the significant clinical value of both 肌顏態® and 金因敷®. They highlighted how 肌顏態®’s patented ingredient, Skbrella FN, demonstrates immense potential in fortifying damaged sensitive skin barriers, effectively mitigating inflammatory erythema, and assuaging discomforts such as burning, tightness, and itching. Furthermore, its capacity to enhance post-laser repair and expedite healing was emphasized. Clinical observations over recent months have evidenced remarkable therapeutic outcomes in patients treated with 肌顏態®, including rapid relief from anesthetic allergies, significant improvement in post-laser inflammatory pigmentation, and restored skin barrier function, leading to exceptionally high patient satisfaction. Similarly, 金因敷® was lauded for its ability to effectively diminish redness, swelling, and pain following medical procedures, thereby accelerating wound healing and considerably shortening recovery periods.

The strategic vision of Uni-Bio Science Group was articulated by CEO Mr. Zhao Zhigang, who emphasized the Group’s unwavering commitment to applying biopharmaceutical standards in the creation of its skincare products. He declared the launch of GeneQueens™ and 金因敷® as a momentous milestone in executing their holistic “Drugs, Medical device and Aesthetics” strategy, designed to deliver full-cycle skin health solutions that cater to the increasingly sophisticated needs of consumers. This ambition is further bolstered by a collaborative effort with Global Cosmetics Group, represented by its President, Ms. Liu Yihua, through a jointly established medical research co-creation biological platform. This partnership leverages gene-editing biosynthesis technology to produce Skbrella FN, a highly bioactive recombinant human fibronectin known as “皮優理,” underscoring the Group’s dedication to cutting-edge science.

A highlight of the event was a grand strategic signing ceremony, symbolizing Uni-Bio Science Group’s successful establishment of in-depth collaborations with numerous renowned medical aesthetics chain institutions and prominent agents. This critical step signifies a strong market endorsement for the quality and immense commercial potential of both GeneQueens™ and 金因敷®. By forging robust alliances with leading channel partners, the Group is strategically positioned to accelerate its commercialization efforts and significantly expand its market reach, ensuring that these innovative products reach core consumers efficiently and unlock substantial commercial value, marking a confident stride into the future of medical beauty and health.